These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 36217805)

  • 1. Population total and unbound pharmacokinetics and pharmacodynamics of ciprofol and M4 in subjects with various renal functions.
    Liu SB; Yao X; Tao J; Yang JJ; Zhao YY; Liu DW; Wang SY; Sun SK; Wang X; Yan PK; Wu N; Liu X; Zhang XJ; Tian X; Liu ZS
    Br J Clin Pharmacol; 2023 Mar; 89(3):1139-1151. PubMed ID: 36217805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetic/pharmacodynamic modeling and exposure-response analysis of ciprofol in the induction and maintenance of general anesthesia in patients undergoing elective surgery: A prospective dose optimization study.
    Liu L; Wang K; Yang Y; Hu M; Chen M; Liu X; Yan P; Wu N; Xiang X
    J Clin Anesth; 2024 Feb; 92():111317. PubMed ID: 37976683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics, pharmacodynamics, and safety of ciprofol emulsion in Chinese subjects with normal or impaired renal function.
    Tao J; Liu S; Zhao YY; Qi L; Yan P; Wu N; Liu X; Liu D; Tian X
    Front Pharmacol; 2023; 14():1260599. PubMed ID: 38074142
    [No Abstract]   [Full Text] [Related]  

  • 4. Population pharmacokinetic-pharmacodynamic modeling and dosing simulation of propofol maintenance anesthesia in severely obese adolescents.
    Chidambaran V; Venkatasubramanian R; Sadhasivam S; Esslinger H; Cox S; Diepstraten J; Fukuda T; Inge T; Knibbe CAJ; Vinks AA
    Paediatr Anaesth; 2015 Sep; 25(9):911-923. PubMed ID: 25975390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic-pharmacodynamic (dipeptidyl peptidase-4 inhibition) model to support dose rationale in diabetes patients, including those with renal impairment, for once-weekly administered omarigliptin.
    Jain L; Chain ASY; Tatosian DA; Hing J; Passarell JA; Kauh EA; Lai E
    Br J Clin Pharmacol; 2019 Dec; 85(12):2759-2771. PubMed ID: 31454094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A preclinical study on online monitoring of exhaled ciprofol concentration by the ultraviolet time-of-flight spectrometer and prediction of anesthesia depth in beagles.
    Li X; Chang P; Liu X; Kang Y; Zhao Z; Duan Y; Zhu T; Liu J; Zhang W
    J Pharm Biomed Anal; 2023 Oct; 235():115621. PubMed ID: 37572595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetic-pharmacodynamic modelling of mycophenolic acid in paediatric renal transplant recipients in the early post-transplant period.
    Dong M; Fukuda T; Cox S; de Vries MT; Hooper DK; Goebel J; Vinks AA
    Br J Clin Pharmacol; 2014 Nov; 78(5):1102-12. PubMed ID: 24837828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug-drug interaction of ciprofol injectable emulsion with mefenamic acid capsules in healthy subjects.
    Yang D; Hu Y; Ruan Z; Jiang B; Wang H; Xu Y; Hu M; Yan M; Lou H
    Br J Clin Pharmacol; 2023 Oct; 89(10):3165-3174. PubMed ID: 37309663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic and pharmacodynamic properties of ciprofol emulsion in Chinese subjects: a single center, open-label, single-arm dose-escalation phase 1 study.
    Teng Y; Ou MC; Wang X; Zhang WS; Liu X; Liang Y; Zuo YX; Zhu T; Liu B; Liu J
    Am J Transl Res; 2021; 13(12):13791-13802. PubMed ID: 35035718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics and pharmacodynamics of ticagrelor and AR-C124910XX in Chinese healthy male subjects.
    Liu S; Xue L; Shi X; Sun Z; Zhu Z; Zhang X; Tian X
    Eur J Clin Pharmacol; 2018 Jun; 74(6):745-754. PubMed ID: 29442148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population Pharmacokinetics and Pharmacodynamics Modelling of Dilmapimod in Severe Trauma Subjects at Risk for Acute Respiratory Distress Syndrome.
    Yang S; Dumitrescu TP
    Drugs R D; 2017 Mar; 17(1):145-158. PubMed ID: 28004376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with acute coronary syndromes.
    Xu XS; Moore K; Burton P; Stuyckens K; Mueck W; Rossenu S; Plotnikov A; Gibson M; Vermeulen A
    Br J Clin Pharmacol; 2012 Jul; 74(1):86-97. PubMed ID: 22242932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics of unbound ceftriaxone in a critically ill population.
    Meenks SD; le Noble JLML; Foudraine NA; de Vries F; Neef K; Janssen PKC
    Int J Clin Pharmacol Ther; 2022 Sep; 60(9):373-383. PubMed ID: 35861497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics of edoxaban and its main metabolite in a dedicated renal impairment study.
    Jönsson S; Simonsson US; Miller R; Karlsson MO
    J Clin Pharmacol; 2015 Nov; 55(11):1268-79. PubMed ID: 25966665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics of total and unbound concentrations of intravenous posaconazole in adult critically ill patients.
    Sime FB; Byrne CJ; Parker S; Stuart J; Butler J; Starr T; Pandey S; Wallis SC; Lipman J; Roberts JA
    Crit Care; 2019 Jun; 23(1):205. PubMed ID: 31171022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating the indotecan-neutropenia relationship in patients with solid tumors by population pharmacokinetic modeling and sigmoidal E
    Beumer JH; Kennard BC; Holleran JL; Moore N; Zlott J; Miller BM; Kummar S; Chen A; Doroshow J; Park W; Gobburu J; Dunn A
    Cancer Chemother Pharmacol; 2023 Mar; 91(3):219-230. PubMed ID: 36813886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Morbid Obesity Alters Both Pharmacokinetics and Pharmacodynamics of Propofol: Dosing Recommendation for Anesthesia Induction.
    Dong D; Peng X; Liu J; Qian H; Li J; Wu B
    Drug Metab Dispos; 2016 Oct; 44(10):1579-83. PubMed ID: 27481855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physiologically-based pharmacokinetic pharmacodynamic parent-metabolite model of edoxaban to predict drug-drug-disease interactions: M4 contribution.
    Xu R; Liu W; Ge W; He H; Jiang Q
    CPT Pharmacometrics Syst Pharmacol; 2023 Aug; 12(8):1093-1106. PubMed ID: 37101392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toward Model-Informed Precision Dosing for Remimazolam: A Population Pharmacokinetic-Pharmacodynamic Analysis.
    Chen Y; Gong C; Liu F; Jiao Z; Zheng X
    Pharmaceutics; 2024 Aug; 16(9):. PubMed ID: 39339160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population Pharmacokinetic-Pharmacodynamic Modeling of Inotersen, an Antisense Oligonucleotide for Treatment of Patients with Hereditary Transthyretin Amyloidosis.
    Yu RZ; Collins JW; Hall S; Ackermann EJ; Geary RS; Monia BP; Henry SP; Wang Y
    Nucleic Acid Ther; 2020 Jun; 30(3):153-163. PubMed ID: 32286934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.